Alto Neuroscience financials
$26.58−0.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$66.4M | -$68.6M |
| Net income | -$63.2M | -$61.4M |
| Net margin | — | — |
| Diluted EPS | $-2.19 | $-2.50 |
| EBITDA | -$65.7M | -$68.1M |
| Operating cash flow | -$51.8M | -$47.4M |
| Free cash flow | -$51.8M | -$49.5M |
| Diluted shares | 28.9M | 24.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $176.5M | $168.2M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $19.0M | $11.6M |
| Total assets | $184.7M | $177.5M |
| Total liabilities | $33.5M | $26.1M |
| Shareholders' equity | $151.1M | $151.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology